Improve Patient Diversity and Expand Access in a Real-World Setting

Boost enrollment in clinical studies that reflects the diversity of the population who will use the medical product.

To meet the goals of the FDA’s efforts to improve diversity in clinical studies, sponsors must incorporate the patient voice, modern patient-centric study designs, and real-world evidence. When planned early in the product development life cycle, strategies for optimizing patient diversity as part of an overall integrated evidence-generation strategy help ensure that clinical studies reflect the racial and ethnic diversity of the population for whom the drug (or device) is being developed.

Read our white paper to learn more about:   

• How to interpret the FDA’s patient diversity policy and guidance
• Why achieving diversity in clinical studies is so important
• What strategies and considerations help to improve diversity

Hear from UBC’s Executive Director, Evidence Development Study Solutions, Judy Lytle, PhD, MBEE, PMP, and Project Manager, Patient & Physician Services, Ewelina Karwowska, on how planning an integrated evidence generation strategy can help you think about diversity holistically and meet your study goals.

For more information about how UBC can optimize your evidence generation strategies, visit here.